Home/Pipeline/Beraprost MR

Beraprost MR

Pulmonary Arterial Hypertension (PAH)

Phase 3Active (ISABELA)

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Phase 3

Status

Active (ISABELA)

Company

United Therapeutics

About United Therapeutics

Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.

View full company profile

Therapeutic Areas

Pulmonary Arterial Hypertension Organ Transplantation Rare Genetic Diseases

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Transdermal Treprostinil Prodrug Patch	Corsair Pharma	Pre-clinical	Active
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Tiprelestat	tiakis Biotech	Phase 2	Active
Seralutinib	Chiesi	Phase 3	Active
Sotatercept	Merck	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
YUTREPIA™ (treprostinil) inhalation powder	Liquidia Corporation	Approved	Approved; Commercial preparation
LIQ861 (treprostinil) inhalation powder	Liquidia Corporation	Phase 3	Active
L606 (liposomal treprostinil) injection	Liquidia Corporation	Preclinical	Investigational
CS1	Cereno Scientific	Phase II	Active; Phase IIa completed, Phase IIb in preparation